Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Differential Muscle Involvement in Mice and Humans Affected by McArdle Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Epigenetic therapy in hematological cancers

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Mandibular advancement device therapy for obstructive sleep apnea: a prospective study on predictors of treatment success

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Actively personalized vaccination trial for newly diagnosed glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Methylation of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene is a predictive and prognostic marker in newly diagnosed glioblastoma patients treated with temozolomide but how MGMT methylation should be assessed to ensure optimal detection accuracy is debated. We developed a novel quantitative methylation-specific PCR (qMSP) MGMT assay capable of providing allelic methylation data and analyzed 151 glioblastomas from patients receiving standard of care treatment (Stupp protocol). The samples were also analyzed by immunohistochemistry (IHC), standard bisulfite pyrosequencing, and genotyped for the rs1690252 MGMT promoter single nucleotide polymorphism. Monoallelic methylation was observed more frequently than biallelic methylation, and some cases with monoallelic methylation expressed the MGMT protein whereas others did not. The presence of MGMT methylation was associated with better overall survival (p = 0.006; qMSP and p = 0.002; standard pyrosequencing), and the presence of the protein was associated with worse overall survival (p = 0.009). Combined analyses of qMSP and standard pyrosequencing or IHC identified additional patients who benefited from temozolomide treatment. Finally, low methylation levels were also associated with better overall survival (p = 0.061; qMSP and p = 0.02; standard pyrosequencing). These data support the use of both MGMT methylation and MGMT IHC but not allelic methylation data as prognostic markers in patients with temozolomide-treated glioblastoma.

OriginalsprogEngelsk
TidsskriftJournal of Neuropathology and Experimental Neurology
Vol/bind75
Udgave nummer3
Sider (fra-til)246-55
Antal sider10
ISSN0022-3069
DOI
StatusUdgivet - mar. 2016

ID: 49459308